|Bid||3.5000 x 3200|
|Ask||3.5300 x 4000|
|Day's range||3.5300 - 3.6900|
|52-week range||0.3500 - 5.5600|
|Beta (5Y monthly)||0.64|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2021 - 12 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||3.46|
GERMANTOWN, Md., October 04, 2021--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the "Plan") in accordance with NYSE American Company Guide Section 711(a).
Investors need to pay close attention to Senseonics (SENS) stock based on the movements in the options market lately.
GERMANTOWN, Md., September 13, 2021--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, and Ascensia Diabetes Care, the makers of the CONTOUR® family of diabetes blood glucose monitoring devices and commercialization partner for Senseonics, have announced that the University Hospitals Accountable Care Organiz